Shi, Fangyi
Lai, Rong
Feng, Li
Zhou, Hongyan
Sun, Xunsha
Shen, Cunzhou
Feng, Jiezhen
Xu, Zhilong
Wang, Haiyan
Feng, Huiyu
Funding for this research was provided by:
National Natural Science Foundation of China (82201555)
Natural Science Foundation of Guangdong (2022A1515010478)
Article History
Received: 18 June 2024
Accepted: 28 January 2025
First Online: 26 February 2025
Declarations
:
: All procedures with human participants’ involvement were following the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This is an observational study, and the local ethics committee for clinical research has confirmed that no ethical approval is required. Before administration of the efgartigimod, we clearly informed the efficacy and AEs of it and fully explained the purpose and content of this study. Moreover, as this is a retrospective study with no additional interventions, the requirement for written informed consent was waived. Every patient who filled out the questionnaire indicated agreement to participate.
: All patients indicated agreement for publication. No personal information of the participants has been disclosed in this manuscript.
: The authors declare no competing interests.